drugset / Trial / NCT02096458

Sensory Evaluation of Dexlansoprazole Delayed-Release Orally Disintegrating Tablets

NCT02096458

Phase 1 Completed 8 enrolled Takeda
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to measure the in-vivo disintegration time of a single dexlansoprazole delayed-release orally disintegrating (OD) tablet.

Timeline

Start
2014-02
Primary completion
2014-02
Completion
2014-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexlansoprazole Other / unclassified 30 mg Oral